Indivior PLC (LON:INDV) insider Lorna Parker purchased 11,529 shares of the firm’s stock in a transaction on Monday, May 13th. The stock was bought at an average price of GBX 43 ($0.56) per share, for a total transaction of £4,957.47 ($6,477.81).
Indivior stock opened at GBX 43.72 ($0.57) on Tuesday. Indivior PLC has a twelve month low of GBX 20.98 ($0.27) and a twelve month high of GBX 504.60 ($6.59). The company has a debt-to-equity ratio of 223.31, a quick ratio of 1.70 and a current ratio of 1.79. The stock has a market capitalization of $312.60 million and a PE ratio of 1.29.
A number of analysts have recently weighed in on the stock. Royal Bank of Canada restated a “sector perform” rating and issued a GBX 130 ($1.70) target price on shares of Indivior in a report on Wednesday, April 10th. Jefferies Financial Group downgraded shares of Indivior to a “hold” rating and reduced their target price for the stock from GBX 118 ($1.54) to GBX 114 ($1.49) in a report on Monday, February 18th. Citigroup restated a “neutral” rating and issued a GBX 150 ($1.96) target price on shares of Indivior in a report on Thursday, May 2nd. Finally, Numis Securities restated a “buy” rating on shares of Indivior in a report on Tuesday, February 5th. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. Indivior presently has an average rating of “Hold” and a consensus target price of GBX 194.40 ($2.54).
Indivior Company Profile
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, opiate overdose, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex.
Featured Story: What is a short straddle?
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.